Differential expression of complement proteins in cerebrospinal fluid from active multiple sclerosis patients

Journal of Cellular Biochemistry

Volumn 112, Issue 7, 2011, Pages 1930-1937

  Li, Yun ^a   Qin, Zhaoyu ^b   Yang, Mingchong ^a   Qin, Yanjiang ^c   Lin, Chengzhao ^b   Liu, Shilian ^a  

^a SHANDONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

2 D Dige; Cerebrospinal fluid; Complement; Multiple sclerosis

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4B; COMPLEMENT FACTOR H; GELSOLIN; HAPTOGLOBIN; TETRANECTIN;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COMPLEMENT SYSTEM PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTEIN INTERACTION MAPPING;

EID: 80051538001     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23113     Document Type: Article

References (40)

1. Bai S, Liu S, Guo X, Qin Z, Wang B, Li X, Qin Y, Liu YH. 2009. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. Mol Vis 15:1638-1648.
2. Barnett MH, Parratt JD, Cho ES, Prineas JW. 2009. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 65:32-46.
3. Chance MR, Chang J, Liu S, Gokulrangan G, Chen DH, Lindsay A, Geng R, Zheng QY, Alagramam K. 2010. Proteomics, bioinformatics and targeted gene expression analysis reveals up-regulation of cochlin and identifies other potential biomarkers in the mouse model for deafness in Usher syndrome type 1F. Hum Mol Genet 19:1515-1527.
4. Compston A, Coles A. 2002. Multiple sclerosis. Lancet 359:1221-1231. (Pubitemid 34304266)
5. Finehout EJ, Franck Z, Lee KH. 2005. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 21:93-101. (Pubitemid 40875153)
6. Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. 2000. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49:171-186. (Pubitemid 30445228)
7. Hammack BN, Fung KY, Hunsucker SW, Duncan MW, Burgoon MP, Owens GP, Gilden DH. 2004. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Multiple Sclerosis 10:245-260. (Pubitemid 38807450)
8. Hinman CL, Stevens-Truss R, Schwarz C, Hudson RA. 1999. Sequence determinants of modified cobra venom neurotoxin which induce immune resistance to experimental allergic encephalomyelitis: molecular mechanisms for immunologic action. Immunopharmacol Immunotoxicol 21:483-506. (Pubitemid 29409363)
9. Iba K, Durkin ME, Johnsen L, Hunziker E, Damgaard-Pedersen K, Zhang H, Engvall E, Albrechtsen R, Wewer UM. 2001. Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformity. Mol Cell Biol 21:7817-7825. (Pubitemid 32988790)
10. Ingram G, Hakobyan S, Robertson NP, Morgan BP. 2009. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol 155:128-139.
11. Ingram G, Hakobyan S, Robertson NP, Morgan BP. 2010. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. J Neuroimmunol 223:124-127.
12. Jans H, Heltberg A, Zeeberg I, Halkjaer Kristensen J, Fog T, Raun NE. 1984. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Neurologica 69:34-38. (Pubitemid 14177934)
13. Jongen PJH, Doesburg WH, Ibrahim-Stappers JLM, Lemmens WAJG, Hommes OR, Lamers KJB. 2000. Cerebrospinal fuid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 101:116-121. (Pubitemid 30051381)
14. Karp NA, Lilley KS. 2005. Maximising sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes. Proteomics 5:3105-3115. (Pubitemid 41176477)
15. Lilley KS, Friedman DB. 2004. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteom 1:401-409. (Pubitemid 43826407)
16. Linington C, Morgan BP, Scolding NJ, Wilkins P, Piddlesden S, Compston DA. 1989. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 112:895-911. (Pubitemid 19199475)
17. Liu S, Bai S, Qin Z, Yang Y, Cui Y, Qin Y. 2009. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med 13:1586-1603.
18. Loeffler DA, Camp DM, Schonberger MB, Singer DJ, LeWitt PA. 2004. Early complement activation increases in the brain in some aged normal subjects. Neurobiol Aging 25:1001-1007. (Pubitemid 38798061)
19. Marouga R, David S, Hawkins E. 2005. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 382:669-678. (Pubitemid 40890994)
20. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127.
21. Morgan BP, Gasque P. 1996. Expression of complement in the brain: role in health and disease. Immunol Today 17:461-466. (Pubitemid 26323314)
22. Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E. 2009. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology 72:602-608.
23. Ottervald J, Franzen B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellstrom S, Marko-Varga G, Vegvari A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T. 2010. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics 73:1117-1132.
24. Pabst H, Day NK, Gewurz H, Good RA. 1971. Prevention of experimental allergic encephalomyelitis with cobra venom factor. Proc Soc Exp Biol Med 136:555-560.
25. Rus H, Cudrici C, Niculescu F, Shin ML. 2006. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. J Neuroimmunol 180:9-16. (Pubitemid 44692324)
26. Sawai S, Umemura H, Mori M, Satoh M, Hayakawa S, Kodera Y, Tomonaga T, Kuwabara S, Nomura F. 2010. Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: proteomic analysis. J Neuroimmunol 218:112-115.
27. Sahu A, Lambris JD. 2000. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 49:133-148. (Pubitemid 30445225)
28. Scott TF, Schramke CJ. 2010. Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later. J Neurolog Sci 292:52-56.
29. Shaw C, Chapman C, Butzkueven H. 2009. How to diagnose multiple sclerosis and what are the pitfalls. Intern Med J 39:792-799.
30. Stoevring B, Jaliashvili I, Thougaard AV, Ensinger C, Hogdall CK, Rasmussen LS, Sellebjerg F, Christiansen M. 2006. Tetranectin in cerebrospinal fluid of patients with multiple sclerosis. Scand J Clin Lab Investig 66:577-583.
31. Stoop MP, Coulier L, Rosenling T, Shi S, Smolinska AM, Buydens L, Ampt K, Stingl C, Dane A, Muilwijk B, Luitwieler RL, Smitt PA, Hintzen RQ, Bischoff R, Wijmenga SS, Hankemeier T, van Gool AJ, Luider TM. 2010. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteom 9:2063-2075.
32. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ, Marra MA. 2002. Generation and initial analysis of more than 15,000 fulllength human and mouse cDNA sequences. Proc Natl Acad Sci USA 99:16899-16903. (Pubitemid 36034070)
33. Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK. 2009. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 35:117-127.
34. Tumani H, Lehmensiek V, Lehnert S, Otto M, Brettschneider J. 2010. 2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Rev Proteom 7:29-38.
35. Vollmer T. 2007. The natural history of relapses in multiple sclerosis. J Neurol Sci 256(Suppl 1): S5-S13. (Pubitemid 46560640)
36. Wang L, Pan Y, Chen D, Xiao Z, Xi Z, Xiao F, Wang X. 2010. Tetranectin is a potential biomarker in cerebrospinal fluid and serum of patients with epilepsy. Clin Chim Acta 411:581-583.
37. Yang YR, Liu SL, Qin ZY, Liu FJ, Qin YJ, Bai SM, Chen ZY. 2008. Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barre syndrome. Cell Mol Neurobiol 28:737-744.
38. Yuan X, Desiderio DM. 2005. Proteomics analysis of human cerebrospinal fluid. J Chrom B Anal Technol Biomed Life Sci 815:179-189. (Pubitemid 40126400)
39. Zajicek JP, Wing M, Scolding NJ, Compston DA. 1992. Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain 115:1611-1631. (Pubitemid 23054856)
40. Zajicek JP, Wing M., et al. 1995. Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system. Lab Invest 73:128-138.